Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Duchenne Muscular Dystrophy Treatment Market size was valued at USD 3.49 billion in 2024 and is set to exceed USD 14.88 billion by 2037, expanding at over 11.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of duchenne muscular dystrophy treatment is evaluated at USD 3.84 billion.
Duchenne muscular dystrophy is an inherited muscular disorder, which results in extreme weakness in muscles. The growth of the market can be attributed to the increasing demand for treatment for Duchenne muscular dystrophy or DMD, along with rising research activities for the development of new treatment methods. Moreover, the growing prevalence of muscular disorders, backed by poor lifestyle and lack of physical activities, are estimated to boost the market growth. According to the data by the World Health Organization (WHO), 1.71 billion people suffer from musculoskeletal disorders. DMD is a type of myositis, which is why, it has no cure. The growing demand for myositis treatment, is anticipated to positively affect the market growth.
Furthermore, DMD is a rare genetic disorder, mostly prevalent amongst males. According to the National Organization of Rare Disorders (NORD), DMD affects approximately 1 in every 3,500 male births worldwide. The high share of male population, in the total global population is projected to promote the global market growth. In 2020, 50.415% of the global population, i.e., 3.907 billion people were male, as per the statistics by the World Bank.
In addition to this, the absence of any permanent treatment for this disorder, along with the growing investment in the R&D activities is estimated to boost the market growth. According to the World Bank data, 2.204% of the global GDP was spent for R&D activities in 2018.
Duchenne Muscular Dystrophy Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Rising Prevalence of Musculoskeletal Disorders
- High Share of Male Population Globally
- Increasing R&D Activities in Healthcare Sector
Challenges
- Difficult Diagnosis of the Disease
- Lack of Health Awareness amongst People in Undeveloped Regions
Duchenne Muscular Dystrophy Treatment Market: Key Insights
Duchenne Muscular Dystrophy Treatment Segmentation
The market is segmented by treatment into corticosteroids, pain management drugs, physical therapy, and others, out of which, the pain management drugs segment is anticipated to hold the largest revenue share in the market over the forecast period. This can be accredited to the high demand for pain management drugs, as DMD can be extremely painful. Moreover, it is primarily diagnosed in kids of age between 3-6 years, who have a lower threshold for pain. Such factors are estimated to further boost the segment growth.
Our in-depth analysis of the global market includes the following segments
|
By Therapy |
|
|
By Treatment |
|
|
By Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportDuchenne Muscular Dystrophy Treatment Industry - Regional Synopsis
APAC Market Statistics
On the basis of geographical analysis, the global Duchenne muscular dystrophy treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. Asia Pacific industry is likely to hold largest revenue share by 2037, due to high prevalence of musculoskeletal diseases in the region. For instance, according to the World Bank, in India, 51.964% of the total population is male, in 2020. Moreover, the constant development in public healthcare services, backed by rapid economic growth, are anticipated to boost the market growth.
North America Market Analysis
The market in the North America region is anticipated to gain the largest market share throughout the forecast period on account of the high health awareness amongst the population, along with easy access of quality healthcare in the developed nations. Furthermore, rising concerns amongst authorities, regarding rising prevalence of genetic diseases, is also estimated to boost the market growth.
Companies Dominating the Duchenne Muscular Dystrophy Treatment Landscape
- Baxter International, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Eli Lilly and Company
- Novartis AG
- Sanofi-aventis Groupe
- Abbott Laboratories
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Siemens Healthcare GmbH
- Pfizer Inc.
- Becton, Dickinson and Company
In the News
-
June, 2021: Novartis AG, the leading pharmaceutical company for global drug distribution, announced to collaborate with Hewlett Packard Enterprise to expand its portfolio in medical devices production.
-
May, 2018: The Myositis Association (TMA) announced May as Myositis Awareness Month, to spread awareness regarding the autosomal muscular disease.
Author Credits: Radhika Pawar
- Report ID: 3814
- Published Date: Dec 24, 2024
- Report Format: PDF, PPT
